Johnson and Johnson Projects Strong 2026 Results Despite Costly Drug Pricing Agreement
Johnson and Johnson expects 2026 sales to exceed market estimates following a pricing deal. The firm reported strong fourth quarter growth in core drugs.
Insights:
Johnson & Johnson announced on Wednesday that it expects its 2026 sales and earnings to surpass Wall Street estimates. This optimistic guidance comes despite the company absorbing hundreds of millions of dollars in costs linked to a drug pricing agreement signed with the Trump administration in the US 
US. The company continues to demonstrate operational resilience as it navigates both a shifting regulatory landscape and ongoing litigation issues.
US. The company continues to demonstrate operational resilience as it navigates both a shifting regulatory landscape and ongoing litigation issues.Under the leadership of Chief Executive Officer Joaquin Duato joaquin duato, the company forecast 2026 operational sales in the range of $99.5 billion to $100.5 billion. This projection is notably higher than the analyst consensus of $98.9 billion. Furthermore, Johnson & Johnsonexpects full-year profit for 2026 to be between $11.43 and $11.63 per share, which exceeds the market expectation of $11.45 per share.
